PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

NCT05751512 · Phase 3 · Recruiting

PHASEPhase 3
STATUSRecruiting
ENROLLMENT180
EST. COMPLETION2027-12

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

MRG003Cetuximab injectionMethotrexate Injection

Study details

SPONSORLepu Biopharma Co., Ltd.
START DATE2023-04-04

Related company profiles

Lepu Biopharma

2157.HK

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT05751512
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record